Familial hypercholesterolemia (FH) is caused by a defective low-density lipoprotein receptor (LDLR), and 41000 mutations in LDLR have been identified. However, in some patients with clinically defined FH, no mutation can be detected within the exons and adjacent intronic segments of the LDLR. We have analyzed RNA extracted from blood samples of patients with clinically defined FH and identified an aberrantly spliced mRNA containing an 81-bp insert from intron 14. The aberrant splicing was caused by a novel intronic mutation, c.2140+86C4G, which activated a cryptic splice site. Although the cryptic splice site does not completely surpass the normal splice site, the mutation was found to cosegregate with high cholesterol levels in a family, which supports the notion that c.2140+86C4G causes FH. The insertion of 81 bp in LDLR mRNA encodes an in-frame insertion of 27 amino acids in the LDLR. However, the insertion was found to hamper LDLR activity by preventing the receptor from leaving the endoplasmic reticulum, probably because of misfolding of the protein. In patients with clinically defined hypercholesterolemia, despite normal results from sequencing of exonic regions of the LDLR gene, characterization of the LDLR mRNA might identify the underlying genetic defect.
INTRODUCTION
Dominantly inherited familial hypercholesterolemia (FH) is a frequent disorder of lipid metabolism caused by mutations in the low-density lipoprotein receptor (LDLR) gene. More than 1000 different mutations in the LDLR gene have been found to be associated with FH. 1 These mutations have been identified by genomic analysis, such as DNA sequencing of PCR products, 2 multiplex ligation-dependent probe amplification 3 and single-strand conformation polymorphisms. 4 Mutations introduce pre-mRNA splicing defects, premature stop codons or amino-acid substitutions in the LDLR protein, rendering the protein unable to fold correctly, bind LDL, be endocytosed or recycled back to the cell surface.
The gene encoding LDLR spans B45 kb and is localized on chromosome 19p13.1-13.3. During pre-mRNA splicing, 18 exons are joined together to create an mRNA of 5.3 kb. Genetic analysis of the LDLR gene has mainly focused on exons and the flanking intron regions. Primers used for PCR amplification of the exons are usually located between 50 and 150 bp upstream and downstream of the exon-intron boundaries.
The prediction of the pathogenic role of sequence alterations in exons is straightforward for nonsense mutations, frameshift mutations or rearrangements that introduce premature stop codons, which cause synthesis of truncated proteins or most likely degradation of mRNA by nonsense-mediated decay. 5 The LDLR is highly conserved and seems to be vulnerable to missense mutations, deletions or insertions, which change the amino-acid composition of the protein. In the Human Gene Mutation database, 1 amino-acid substitutions at approximately half of the 860 residues that constitute the LDLR have been reported to be associated with FH. Whether the association is the result of amino-acid substitution or is caused by deleterious effects on the LDLR mRNA composition has not been systematically analyzed. Correct pre-mRNA splicing is a prerequisite for a functional LDLR. Pre-mRNA splicing defects might cause exon skipping, intron inclusions or activation of cryptic splice sites. Prediction of the pathogenic role of sequence alterations that might disrupt pre-mRNA splicing is less straightforward.
Mutations throughout the LDLR exons and introns might cause pre-mRNA splicing defects, and might account for some unresolved cases of clinically defined hypercholesterolemia. Synonymous mutations and intronic mutations are likely to be overlooked during genetic analysis of the LDLR gene or are likely to be undetected, as point mutation screening of all intronic sequences is not yet feasible. Direct analysis of mRNA from a patient is the most reliable method for studying pre-mRNA splicing; as LDLR is expressed in leukocytes, 6 total RNA isolated from blood samples can be used as the RNA source.
We have established a reverse transcription (RT)-PCR screening assay for patients with clinically defined FH without any mutations detected in the LDLR gene in routine DNA sequencing and multiplex ligation-dependent probe amplification. We have identified a mutation located at position c.2140+86, which activates a cryptic splice site in intron 14 of the LDLR gene. The mutation was located outside the region covered by DNA sequencing. c.2140+86C4G causes an inclusion of 81 nucleotides that encode an in-frame insertion of 27 amino acids. The mutation was found to cosegregate with high cholesterol levels in a family.
MATERIALS AND METHODS

Patient samples
Patients with clinically defined FH and total cholesterol levels above 10 mmol l À1 and triglyceride levels below 5 mmol l À1 were subjected to screening by RT-PCR. No mutations were detected in these patients by routine genomic analysis of the LDLR. Moreover, neither the R3500Q mutation in the apolipoprotein B gene nor a PCSK9 gain-of-function mutation had been identified in these patients. Family members of the index patient were recruited to undergo segregation analysis. Written informed consent for molecular genetic analysis was obtained from all participants.
RNA isolation, RT-PCR
Blood samples were collected into PAXgene Blood RNA tubes and total RNA was extracted using the PAXgene Blood RNA kit (Qiagen, Valencia, CA, USA). RT-PCR was performed using 200 ng of total RNA and the Qiagen OneStep RT-PCR kit (Qiagen). The primers used are described in the study by Tveten et al. 6 and designed to produce overlapping PCR products corresponding to exons 1-8, 3-10, 7-14, 11-17 and 13-18. The thermal cycling conditions were 50 1C for 30 min, 95 1C for 15 min, followed by 35 cycles of 95 1C for 30 s, 60 1C for 30 s and 72 1C for 60 s. The amplified products were analyzed on Criterion 5% TBE gels (Bio-Rad, Hercules, CA, USA), which were stained with ethidium bromide. To characterize the bands, the amplified products were cloned into the pCRII-TOPO vector (Invitrogen, Carlsbad, CA, USA). Subcloned fragments were reamplified using relevant primers and sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and analyzed on a 730 Genetic Analyzer (Applied Biosystems).
DNA analysis
DNA was extracted from EDTA-containing blood using a DNA extractor (Mole Genetics, Oslo, Norway). A DNA fragment consisting of LDLR exons 13 and 14 was amplified in a PCR using AmpliTaqGold, the upstream primer 5¢-TGGCCTGTGTCTCATCCCAGTGTTT-3¢ and the downstream primer 5¢-GGCTCCTGTCAGAAATCAGATCACC-3¢. The thermal cycling conditions were 95 1C for 10 min, followed by 36 cycles of 95 1C for 30 s, 61 1C for 30 s and 72 1C for 60 s. The PCR product was purified using ExoSAP-IT (USB Corporation, Cleveland, OH, USA) according to the manufacturer's instructions. Version 3.1 of the BigDye terminator cycle-sequencing kit (Applied Biosystems) and the downstream primer were used for the sequencing reactions according to the manufacturer's instructions. The sequencing products were run on a Genetic Analyzer 3730 (Applied Biosystems) and analyzed using Seqscape version 2.5 software (Applied Biosystems).
Site-directed mutagenesis
The QuikChange XL Site-directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) was used to insert 81 bp of the 5¢-end of LDLR intron 14 between exons 14 and 15 in the pcDNA4-LDLR. 7 To generate pcDNA4-LDLRins81 bp, the oligonucleotide 5¢-CATGAGGAGCTGCCTCACAGGTGTGGCACACGCC TTGTTTCTGCGTCCTGTGTCCTCCAACTGCCCCCTCCTGAGCCTCTCTC TGCTCATCTGTCAAATGGAGGCTGAGGCTGCAGTGGCC-3¢ (81 bp insertion underlined) and its complementary oligonucleotide were obtained and PAGE purified by Medprobe (Oslo, Norway). The integrity of the pcDNA4-LDLRins81 bp plasmid was confirmed by DNA sequencing.
Computer analysis
The strength of the normal and cryptic donor splice site was calculated using algorithms developed by Burge laboratory, 8 including MAXENT (maximum entropy), MDD (multiple dependence decomposition), a first-order MM (Markov's model) and a WMM (weight matrix model) using their web-based tool MaxEntScan (http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq. html), which scores short input sequences (9mer) containing a single splice site.
To screen for transposable elements in the LDLR DNA sequence, the RepeatMasker program (http://www.repeatmasker.org) created by Smit (AFA Smit et al., unpublished data) was used.
Cell culture and transient transfection T-REx CHO cells (Invitrogen) stably expressing a tetracycline repressor were maintained in complete medium: Ham's F-12 medium (Euroclone) supplemented with 10% (v/v) fetal calf serum (Euroclone, West York, UK), 50 Units ml À1 penicillin (Euroclone), 50 mg ml À1 streptomycin (Euroclone) and 10 mg ml À1 blasticidin (Invitrogen) in a humidified atmosphere (37 1C, 5% CO 2 ). T-REx CHO cells were transiently transfected with pcDNA4-LDLR or pcDNA4-LDLRins81bp using Lipofectamine 2000 (Invitrogen). The cells were incubated with transfection mixture for 6 h at 37 1C; thereafter, the medium was changed to complete medium and the cells were incubated for another 48 h, the last 24 h with 1 mg ml À1 tetracycline (Invitrogen).
Western blot analysis
Cells were lysed and subjected to western blot analysis as described in the study by Tveten et al. 9 The membrane was cut in two. The upper part was immunostained with rabbit polyclonal anti-LDLR (Fitzgerald Industries Intl, North Acton, MA, USA; diluted 1:500 in 5% (w/v) nonfat dry milk (Bio-Rad) and 0.05% (v/v) Tween-20 (Sigma-Aldrich, St Louis, MO, USA)), whereas the lower part was immunostained with rabbit anti-tubulin (Nordic BioSite, Täby, Sweden; diluted 1:1000). After incubation at room temperature for 1 h, both were counterstained with horseradish peroxidase-conjugated anti-rabbit antibodies (diluted 1:1000; GE Healthcare, Waukesha, WI, USA). Signals were developed using SuperSignal West Dura Extended Duration Substrate (Pierce Biotechnology, Rockford, IL, USA), and ChemiDoc XRS (Bio-Rad) was used to detect the signals. The concentrations of the antibodies were optimized to achieve low background and a dose-dependent increase in signal intensity.
RESULTS
Blood samples collected from 30 unrelated patients with clinically defined hypercholesterolemia, but without any mutations detected by standard DNA analysis, were recruited for RNA analysis. Overlapping RT-PCR was performed as described by Tveten et al. 6 RT-PCR amplification of RNA from an index patient revealed several longer amplicons in the RT-PCR of exons 11-17 and exons 13-18, with one major product being B 80 bp longer than the normal amplicon ( Figure 1) . Sequencing of RT-PCR products revealed that the major product contained an insertion of 81 bp from the 5¢-end of intron 14. To identify the underlying mutation, we performed a PCR amplification of exons 13 and 14 from the patient's DNA using a downstream primer located further downstream in intron 14 (c.2140+220). DNA sequencing of the PCR product detected a novel intronic mutation c.2140+86C4G. This mutation is located outside the region covered by DNA sequencing of the LDLR in our laboratory, where the 5¢-end of the downstream primer for amplification of exons 13 and 14 was located at c.2140+89.
The mutation c.2140+86C4G introduces a cryptic splice site by exchanging a cytosine to a guanine in the fifth position of the novel splice site. The substitution increases the similarity with the donor splice site consensus and causes an increase in the splice site score of the sequence located at positions +79 to +87 to the level of the normally used donor splice site located at the 5¢-end of intron 14 (Table 1) .
Segregation analysis was performed in the family of the index patient. Of 23 family members, 12 were shown to be heterozygous for the mutation and c.2140+86C4G was found to cosegregate with high cholesterol levels (Figure 2a) . Mutation carriers had a total cholesterol level of 8.5 mmol l À1 , compared with 5.3 mmol l À1 in noncarriers, which represented a significant increase in total cholesterol (P¼0.000013) (Figure 2b) .
Among 550 index patients referred to us for genetic testing, c.2140+86C4G has been detected in 3 other index patients. In the family one of these patients, the mutation was found in six of seven tested members ( Figure 3 ) and they all had LDL cholesterol levels above the 97th percentile. The aberrant splicing, causing the insertion of 81 bp from the 5¢-end of intron 14, was confirmed in one member (II.2) of this family (results not shown).
Generation of a cryptic splice site might completely surpass the use of the normal splice site, or both may be used in various degrees. To establish the degree of detrimental effect caused by c.2140+86C4G on the splicing process, the RT-PCR products generated from II.2 ( Figure 3 ) were cloned in a pCRII-TOPO vector to reveal whether the mutant allele could give rise to correctly spliced LDLR mRNA. II.2 is heterozygous for a common synonymous single-nucleotide polymorphism in exon 13, c.1959T4C, and the linkage between this single-nucleotide polymorphism and the insertion of 81 bp was established by sequencing individual clones transfected with the pCRII-TOPO vector containing the RT-PCR amplicons. A total of 160 clones were isolated and subjected to DNA sequencing. Of them, 90 had a thymidine in position c.1959 and no insert, whereas 70 had a cytosine in position c.1959; of these 70 clones, 46 had an 81 bp insert from the 5¢-end of intron 14, whereas 24 had no insert. The mutant allele contributed with 21% of normal transcripts. Thus, the allele containing the mutation c.2140+86C4G mainly gives rise to aberrantly spliced mRNA, but a significant production of normal mRNA might also be produced.
The inserted 81 bp from the 5¢-end of intron 14 encodes an inframe insertion of 27 amino acids. These amino acids are inserted at the end of EGF-repeat C in the LDLR. To examine the effect on the protein, 81 bp was inserted between exons 14 and 15 in the cDNA encoding human wild-type LDLR. Wild-type LDLR cDNA and LDLRins81 bp cDNA were transfected into CHO cells and cell lysates were analyzed on a western blot. As seen in Figure 4 , the LDLR with the 27 amino-acid insert did not undergo oligosaccharide modifications in the Golgi apparatus, which increase the apparent molecular mass of the wild-type LDLR from B120 to 160 kDa. 10 
DISCUSSION
By performing RT-PCR analysis on mRNA from individuals with clinically defined FH, we discovered a novel mutation located within intron 14 of the LDLR. The mutation, c.2140+86C4G, introduces a cryptic splice site that results in an in-frame insertion of 81 bp from the 5¢-end of intron 14 in the LDLR mRNA. The cryptic splice site does not completely surpass the normal splice site. A small amount of normal transcript is produced from the mutant allele. However, the majority of transcripts produced from the mutant allele are abnormal and cosegregation of the mutation with high cholesterol levels in a family supports the notion that c.2140+86C4G causes FH. The insertion of 81 bp in the LDLR mRNA encodes an in-frame insertion of 27 amino acids in the LDLR. However, the insertion causes a retention of the receptor in the endoplasmic reticulum, probably caused by misfolding of the protein.
RT-PCR analysis on RNA from patients with a definite diagnosis, but without any identified disease-associated mutations after routine DNA sequencing, might solve some unsolved cases. Engel et al. analyzed the RNA from five consecutive ornithine transcarbamylasedeficient patients in whom genomic ornithine transcarbamylase analysis had failed to show a disease-associated mutation. Ornithine transcarbamylase pre-mRNA splicing aberrations caused by deep intronic mutations were found in all five patients. As genetic testing improves and becomes more widely requested, RT-PCR analysis will also be important to interpret the clinical significance of unclassified sequence variants. 12 To perform RT-PCR analysis, an appropriate RNA source has to be available. Peripheral blood is an easily accessible source. However, not all genes are expressed in leukocytes. 13 The LDLR is expressed in leukocytes, although it fulfills its most important role in the liver, which is clearing lipoproteins from circulation. Spurdle et al. 14 emphasize the importance of determining the relative amounts of aberrantly spliced products generated by a variant allele to establish clinical relevance. Mutation Figure 4 Western blot analysis of cell lysates from TRex-CHO cells transfected in duplicate with wild-type LDLR or LDLRins81 bp. Cell lysates were prepared and equal amounts of protein were subjected to SDS-PAGE and western blot analysis, using an antibody against LDLR (upper part) and an antibody against tubulin (lower part). The experiment was conducted twice with similar results. LDLR, low-density lipoprotein receptor.
c.2140+86C4G gives rise to several incorrect transcripts. However, in leukocytes, a significant amount (21%) of the normally spliced transcripts was produced from the mutant allele, indicating that the c.2140+86C4G mutant allele is not a null allele. However, the mutation cosegregated with high cholesterol levels in a family, which is strong evidence that c.2140+86C4G causes FH. Alternative splicing is known to be tightly regulated in different tissues and developmental stages because of tissue-specific expression and/or activation of splicing factors. 15 It is therefore likely that the tissue/developmental variation in splicing factors might also affect the outcome of a mutation and reduce or amplify the degree of aberrant splicing. 14 The relative amount of aberrantly spliced LDLR mRNA was analyzed in blood samples. However, whether leukocytes are representative for hepatic tissue in this context is uncertain.
Inclusion of intronic sequences in mRNA has been found to be an important cause of hereditary diseases, and the inclusion is often caused by activation of splice sites in transposable elements located within introns. 16 The mutation c.2140+86C4G is located within a region containing a segment of a mammalian interspersed repeat (MIRb). The match obtained by Repeat Masker started at c.2140+47 and extended to c.2140+112 ( Figure 5 ). Vorechovsky et al. 16 found that transposable elements contributed to cryptic exon activation in B50% of the mutation-induced intron inclusions in patients with hereditary diseases. Overall, 60% of the LDLR gene consists of transposable elements and, with the exception of the 3¢-untranslated region, they are located within introns. Intronic mutations within these elements might be an underappreciated cause of FH.
By RT-PCR analysis of RNA from blood samples of individuals with clinically definite hypercholesterolemia, we have identified a novel intronic mutation causing FH. When routine DNA sequencing fails to identify a disease-causing mutation, the next step in diagnostic investigation should be RNA analysis. 
